Gilead’s HIV prevention business exceeded $1 billion in quarterly sales for the first time, driven by Descovy’s daily pill growth and strong early uptake of Yeztugo. The company reported Q2 PrEP sales of $1.03 billion, with Yeztugo contributing $232 million and surpassing consensus. Despite the beat, analysts questioned the durability of Yeztugo’s trajectory, pointing to unchanged full-year forecasting around $1 billion and uncertainties tied to a potential weekly oral option based on the same lenacapavir ingredient. Gilead also cited persistence of more than 70% for six-month returns, setting it apart from other options, although long-term maintenance remains an open question. For biotech stakeholders, the key takeaway is that prevention economics are tightening around persistence metrics and modality choice as pipeline peers prepare competing switch strategies.